Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality

Nat Commun. 2019 Nov 13;10(1):5100. doi: 10.1038/s41467-019-13088-3.

Abstract

Endowing chimeric antigen receptor (CAR) T cells with additional potent functionalities holds strong potential for improving their antitumor activity. However, because potency could be deleterious without control, these additional features need to be tightly regulated. Immune pathways offer a wide array of tightly regulated genes that can be repurposed to express potent functionalities in a highly controlled manner. Here, we explore this concept by repurposing TCR, CD25 and PD1, three major players of the T cell activation pathway. We insert the CAR into the TCRα gene (TRACCAR), and IL-12P70 into either IL2Rα or PDCD1 genes. This process results in transient, antigen concentration-dependent IL-12P70 secretion, increases TRACCAR T cell cytotoxicity and extends survival of tumor-bearing mice. This gene network repurposing strategy can be extended to other cellular pathways, thus paving the way for generating smart CAR T cells able to integrate biological inputs and to translate them into therapeutic outputs in a highly regulated manner.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Gene Editing
  • Humans
  • Immune System / metabolism*
  • Interleukin-12 / genetics
  • Lymphocyte Activation / immunology
  • Mice
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Chimeric Antigen / immunology*
  • T-Lymphocytes / immunology*
  • Transcription Activator-Like Effector Nucleases / metabolism

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • Interleukin-12
  • Transcription Activator-Like Effector Nucleases